Navigation Links
Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management
Date:1/18/2008

BALTIMORE, Jan. 18 /PRNewswire/ -- Alba Therapeutics Corporation today announced the appointment of Wendy Perrow, as Vice President, Marketing and Alliance Management. In this role, Ms. Perrow will be responsible for leading Alba's marketing development strategy and program execution through product approval and commercialization. Ms. Perrow will also serve as a member of Alba's executive management leadership team.

"We are very pleased to announce that Ms. Perrow is joining Alba in this critical leadership role. Wendy is an accomplished executive with extensive experience in pharmaceutical marketing including both US and global product launches and programs to increase brand use and awareness," said Blake Paterson, M.D., Alba's Chief Executive Officer. "Her leadership in our brand creation and marketing efforts, and management of our corporate alliances will be essential for our success in developing AT-1001 (larazotide acetate) as the first drug for celiac disease," added Dr. Paterson.

"Alba is focused on discovering and commercializing novel therapies for patients with serious autoimmune and inflammatory conditions. It is wonderful to join this innovative organization that is dedicated to bringing new medicines to patients who need them and help change the course of disease," said Ms. Perrow.

Prior to joining Alba, Ms. Perrow held senior executive marketing positions with private and public pharmaceutical companies. From 2004 to 2007, Ms. Perrow was Vice President of Marketing for Sigma-Tau Pharmaceuticals, Inc., a company focused on creating novel therapies for the unmet needs of patients with rare diseases. Her experience ranges from oncology, bone marrow transplant, metabolic disorders, and renal disease. From 1989 to 2003, Ms. Perrow was at Merck and Co., Inc. in the areas of global marketing and U.S. marketing in the areas of Anti-Hypertensives, Vaccines, Cholesterol, and GI. At Merck, she held positions in marketing promotion, international business research analysis, training, and sales. Ms. Perrow began her career in a division of Johnson & Johnson. A skilled marketer, she has led U.S. and global initiatives for leading products that have significantly increased brand awareness and has launched medicines for unmet medical needs.

Ms. Perrow holds a bachelors degree from Eastern Illinois University and a Masters of Business Administration degree in finance and marketing from Duke University - The Fuqua School of Business.

About Alba

Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical company based in Baltimore, Maryland. Alba is dedicated to the development and commercialization of disease-modifying therapeutics to treat autoimmune and inflammatory diseases, drug delivery agents and mucosal vaccine adjuvants by exploiting its technology to regulate the assembly and disassembly of tight junctions in cell barriers throughout the body. Alba's lead compound, AT-1001 (Larazotide acetate), is targeted toward the treatment of Celiac Disease, Inflammatory Bowel Disease and Type 1 Diabetes.

Contact: Dr. Bernard McDonald

Phone: 410-319-0780

E-mail: info@albatherapeutics.com

Website: http://www.albatherapeutics.com


'/>"/>
SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
2. Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale
3. Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
4. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
5. Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors
6. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
7. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
8. Sirnaomics Received Multiple Government Fundings For Its Multi-Targeted siRNA Therapeutics Programs
9. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
10. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
11. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... September 25, 2017 , ... Bluebird, Inc. , ... that they have been successfully integrated with a national database provided by the ... in the region. , Bluebird biometric lineup that have been approved to ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... Communications (UC) and Collaboration company, and Bigleaf Networks, the cloud-first SD-WAN platform ... alliance to extend CallTower’s Unified Communication applications with integrated Bigleaf SD-WAN service. ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... studies, presentations and demonstrations at SCDM 2017, held September 24-27, 2017 in ... teams and CRO partners for more automated capabilities across evolving data, Comprehend ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... will host a booth at premier packaging event PACK EXPO International in Las ... Packaging Machinery Manufacturers Institute (PMMI). , At this year’s PACK EXPO at the ...
Breaking Biology Technology:
(Date:4/19/2017)... 2017 The global military biometrics ... marked by the presence of several large global players. ... five major players - 3M Cogent, NEC Corporation, M2SYS ... nearly 61% of the global military biometric market in ... global military biometrics market boast global presence, which has ...
(Date:4/11/2017)... PALM BEACH GARDENS, Fla. , April 11, ... biometric identity management and secure authentication solutions, today ... million contract by Intelligence Advanced Research Projects Activity ... technologies for IARPA,s Thor program. "Innovation ... the onset and IARPA,s Thor program will allow ...
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
Breaking Biology News(10 mins):